FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

FDA Approves Auvelity for Agitation in Alzheimer's Dementia

The U.S. Food and Drug Administration (FDA) has approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease in adults. This marks the first non-antipsychotic drug approved for this condition. Auvelity was previously approved in 2022 for major depressive disorder. The approval is based on two randomized studies (NCT 03226522 and NCT 04947553) which demonstrated Auvelity's efficacy, showing significant superiority over placebo in reducing agitation symptoms and extending the time to relapse. The approval was granted to Axsome Therapeutics.

• Efficacy Demonstrated in Two Randomized Trials: The first study (NCT 03226522), a five-week trial, showed Auvelity was significantly superior to placebo in improving the Cohen-Mansfield Agitation Inventory (CMAI) total score, which assesses the frequency of agitated behaviors. The second study (NCT 04947553) was a withdrawal trial where patients who responded to Auvelity and continued treatment experienced a significantly longer time to relapse of agitation symptoms compared to those switched to placebo.
• First Non-Antipsychotic Treatment for Agitation in Alzheimer's: Auvelity represents a significant advancement as the first FDA-approved non-antipsychotic treatment specifically for agitation associated with dementia due to Alzheimer's disease. This provides an additional important option for patients and families dealing with this challenging and distressing symptom, which can severely impact quality of life for both patients and caregivers.
• Safety Profile and Important Warnings: Common side effects include dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction, and uncontrolled sweating. Auvelity carries a Boxed Warning regarding an increased risk of suicidal thoughts and behaviors in adolescents and young adults. Healthcare providers must monitor patients, especially during initial treatment, and assess for seizure risk, elevated blood pressure, and potential activation of mania or hypomania.

Why a Non-Antipsychotic Option for Alzheimer's Agitation?

Current treatment approaches for agitation in Alzheimer's disease face significant safety and efficacy challenges that limit their clinical utility. The modest benefits of existing pharmacological interventions are overshadowed by concerning adverse effect profiles, while non-pharmacological approaches lack robust evidence of effectiveness.

• Limited efficacy and high safety risks with antipsychotics - Off-label use of atypical antipsychotics shows only modest clinical benefits while carrying high side-effect burden and increased mortality risk

• Inadequate evidence base for treatment decisions - Literature consists largely of uncontrolled trials, case reports, and methodologically questionable randomized controlled trials that have produced disappointing results

• Substantial adverse effects with current pharmacological options - Traditional neuroleptics worsen cognitive functioning, while sedatives and antipsychotics cause multiple undesirable side effects with troubling safety concerns

• Insufficient evidence for non-pharmacological interventions - Despite being recommended as first-line treatment with fewer side effects, non-pharmacological alternatives have demonstrated benefit only in certain cases due to research design limitations

• Complex trial design challenges - Designing studies for dementia populations presents difficulties in participant identification, patient and caregiver engagement and compliance, and selection of optimal outcome measures to demonstrate treatment effectiveness

• Disappointing results from novel drug development - Recent trials of promising agents including mibampator, dextromethorphan/quinidine, and cannabinoids have shown limited benefits, potentially due to absence of biological links to neuropsychiatric symptoms and methodological issues

• High heterogeneity in research approaches - Recent randomized controlled trials demonstrate significant design heterogeneity, limiting the ability to draw definitive conclusions about treatment effectiveness across studies

Pivotal Data Supporting Auvelity's Efficacy

Clinical trials for agitation associated with dementia due to Alzheimer's disease demonstrate significant heterogeneity in design parameters, assessment methods, and outcome measures. Recent systematic reviews have identified quality issues across published randomized controlled trials, including high dropout rates and inconsistent reporting of randomization procedures.

Understanding Auvelity's Safety and Tolerability Profile

Published safety and tolerability data for dextromethorphan hydrobromide and bupropion hydrochloride demonstrate a generally favorable profile across multiple indications, with the most comprehensive data available for major depressive disorder. In MDD clinical trials from 2022-2024, the most frequently reported adverse events include dizziness, nausea, headache, dry mouth, decreased appetite, and anxiety. Network meta-analysis data from 2025 shows a higher incidence of mild to moderate adverse events with the combination therapy (72.9%) compared to bupropion monotherapy (64.6%), though this increased incidence did not translate to significantly higher treatment discontinuation rates. Notably, the combination was not associated with psychotomimetic effects, weight gain, or sexual dysfunction in phase 3 trials.

Beyond MDD, limited safety data exists for other indications including agitation in Alzheimer's disease and neuropathic pain, where the combination appears generally well-tolerated. Early clinical trial data for agitation in Alzheimer's disease indicates good tolerability, while studies in neuropathic pain identify light-headedness as the primary adverse effect at higher dextromethorphan doses (270 mg). Historical studies in stroke patients and pediatric cardiac surgery populations showed no significant toxicity signals, though these involved smaller patient populations and different dosing regimens.

Important safety considerations include established warnings for seizure risk associated with high-dose bupropion and neurologic side effects related to dextromethorphan metabolites. The formulation carries a boxed warning regarding increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Drug interaction studies demonstrate low inhibitory potency versus CYP2D6, and enhanced metabolic stability through deuteration may reduce dextromethorphan metabolite-associated neurological side effects. Overall, the combination maintains a safety profile comparable to bupropion monotherapy while providing unique rapid-acting antidepressant benefits.

Auvelity's Approval: A New Era for AD Agitation Treatment

The recent FDA approval of Auvelity for agitation associated with Alzheimer’s disease dementia marks a significant milestone, offering the first non-antipsychotic treatment option for this challenging condition. This approval is particularly impactful given the substantial unmet need in managing agitation, a prevalent and distressing symptom that significantly diminishes quality of life for patients and caregivers alike. Historically, clinicians have relied on off-label antipsychotics, which, despite some efficacy, are associated with serious safety concerns, including increased mortality risk. Auvelity's novel mechanism, combining dextromethorphan's NMDA receptor antagonism with bupropion's role as a CYP2D6 inhibitor to enhance dextromethorphan's bioavailability, alongside its dopamine-norepinephrine reuptake inhibition, provides a differentiated therapeutic approach.

This strategic approval not only expands Auvelity's utility beyond its existing major depressive disorder indication but also positions it as a potential new standard of care. For Axsome Therapeutics, this represents a successful lifecycle management strategy, tapping into a large and vulnerable patient population. However, several considerations warrant attention:

• The bupropion component, while generally well-tolerated for depression, has been linked to acute neurologic or psychotic symptoms, especially in elderly or renally impaired individuals. Careful monitoring and dose adjustment will be crucial in the AD population.

• While effective for agitation, bupropion monotherapy did not show superiority over placebo for apathy in AD patients without depression, and placebo even demonstrated greater improvement in overall neuropsychiatric symptoms in that context. This suggests Auvelity's benefit may be specific to agitation rather than a broad improvement across all neuropsychiatric symptoms of AD.

• As an antidepressant, Auvelity carries a boxed warning for increased suicidal thoughts and behaviors in younger patients, a class effect that, while less directly relevant to the elderly AD population, underscores the need for vigilance regarding its psychiatric effects.

This approval opens a new chapter for AD symptom management, providing a much-needed alternative to antipsychotics. Its success will hinge on careful patient selection, robust post-market surveillance, and effective communication of its unique benefits and risks to clinicians and caregivers.